Evidence map›Paper›PMID 28539345›Full record

ReviewJournal of clinical microbiology2017

Point-of-Care Testing for Infectious Diseases: Past, Present, and Future.

Thomas R Kozel, Amanda R Burnham-Marusich

Abstract readReview
In one paragraph

Review in Journal of clinical microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 168 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
168citing papers in PubMed, 10 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

168 citing papers in PubMed, 10 syntheses or guidelines pooled it.

  1. Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.The Cochrane database of systematic reviews · 2025
    Pooled it
  2. Pooled it
  3. Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.The Cochrane database of systematic reviews · 2022
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Assessing the potential of upper respiratory tract point-of-care testing: a systematic review of the prognostic significance of upper respiratory tract microbes.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2019
    Pooled it
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Observational

108 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Thomas R KozelDepartment of Microbiology & Immunology, University of Nevada, Reno School of Medicine, Reno, Nevada, USA; DxDiscovery, Inc., Reno, Nevada, USA tkozel@med.unr.edu.
Amanda R Burnham-MarusichDepartment of Microbiology & Immunology, University of Nevada, Reno School of Medicine, Reno, Nevada, USA; DxDiscovery, Inc., Reno, Nevada, USA.

Funding

Point-of-care lateral flow immunoassay for diagnosis of pertussisR44AI109891 · NIAID · DXDISCOVERY, INC. · PI BURNHAM-MARUSICH, AMANDA · 2016 to 2025
$4.0M
Immunoassay for capsular antigen for rapid diagnosis of anthraxR01AI093365 · NIAID · UNIVERSITY OF NEVADA RENO · PI KOZEL, THOMAS R · 2011 to 2015
$3.4M
Target discovery and immunoassay for diagnosis of invasive aspergillosisR33AI085548 · NIAID · UNIVERSITY OF NEVADA RENO · PI AUCOIN, DAVID P, KOZEL, THOMAS R · 2012 to 2014
$1.1M
Biomarker discovery for immunodiagnosis of invasive candidiasisR41AI108114 · NIAID · DXDISCOVERY, INC. · PI KOZEL, THOMAS R · 2013 to 2014
$600k
Point-of-care immunoassay for early diagnosis of pertussisR43AI109891 · NIAID · DXDISCOVERY, INC. · PI BURNHAM-MARUSICH, AMANDA, KOZEL, THOMAS R · 2014 to 2015
$590k
Point of care immunoassay for rapid diagnosis of tinea capitisR43EB023408 · NIBIB · DXDISCOVERY, INC. · PI BURNHAM-MARUSICH, AMANDA, KOZEL, THOMAS R · 2016 to 2017
$421k
NIAID NIH HHS R01 AI093365NIAID NIH HHS R33 AI085548NIAID NIH HHS R41 AI108114NIAID NIH HHS R43 AI109891NIAID NIH HHS R44 AI109891NIBIB NIH HHS R43 EB023408
6 · The paper itself

Abstract

Point-of-care (POC) diagnostics provide rapid actionable information for patient care at the time and site of an encounter with the health care system. The usual platform has been the lateral flow immunoassay. Recently, emerging molecular diagnostics have met requirements for speed, low cost, and ease of use for POC applications. A major driver for POC development is the ability to diagnose infectious diseases at sites with a limited infrastructure. The potential use in both wealthy and resource-limited settings has fueled an intense effort to build on existing technologies and to generate new technologies for the diagnosis of a broad spectrum of infectious diseases.

Indexed as

Chromatography, AffinityCommunicable DiseasesHumansMolecular Diagnostic TechniquesPoint-of-Care Testinginfectious diseaselateral flow immunoassaymolecular diagnosticpoint-of-carerapid tests

Identifiers

PMID28539345
PMCPMC5527409

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.